Novogen chair-elect steps down suddenly
20 November, 2014 by Dylan Bushell-EmblingIain Ross, the director due to replace Dr Graham Kelly as chairman of the board of Novogen (ASX:NRT), has stepped down suddenly citing an unanticipated conflict of interest.
Funding dementia research
19 November, 2014The Alzheimer's Australia Dementia Research Foundation will award grants and fellowships worth $2.4 million to 25 early-career researchers.
Reducing salt prevents kidney failure
18 November, 2014Reducing salt intake can reduce the warning signs of higher urinary albumin that is indicative of kidney and heart disease.
Viralytics wins nod for phase I Cavatak trial
17 November, 2014 by Dylan Bushell-EmblingViralytics (ASX:VLA) has secured approval for a phase I trial of Cavatak in non-muscle invasive bladder cancer, to be conducted in the UK in the first quarter of 2015.
Novogen CEO to hand over chairman role
12 November, 2014 by Dylan Bushell-EmblingWith Novogen (ASX:NRT) moving to take anticancer candidate Cantrixil into the clinic, the company is making moves to line up funding and allow it to better focus on clinical development.
Cavatak combines with immune checkpoint inhibitors
10 November, 2014 by Dylan Bushell-EmblingViralytics (ASX:VLA) said preclinical data suggests that its Cavatak anticancer candidate performs better when combined with immune checkpoint inhibitors.
Patrys postpones PAT-SM6 trial
07 November, 2014 by Dylan Bushell-EmblingPatrys (ASX:PAB) has advised that complications in the manufacturing process are likely to delay the commencement of a planned trial of PAT-SM6 in multiple myeloma until 2Q15.
Potential new approach to treating diabetes
07 November, 2014Regulating beta cell stress provides a potential new approach to treating diabetes.
Prima's CVac improves OS in ovarian cancer trial
06 November, 2014 by Dylan Bushell-EmblingPrima BioMed's (ASX:PRR) CVac candidate is demonstrating a clear trend in improved overall survival in patients with second remission ovarian cancer.
STA expands PBS listing for cancer drug
03 November, 2014 by Dylan Bushell-EmblingSpecialised Therapeutics Australia's cancer drug Abraxane will now receive PBS reimbursed in metastatic pancreatic cancer, expanding its initial listing covering metastatic breast cancer.
Novogen to raise up to $7.5m in placement
03 November, 2014 by Dylan Bushell-EmblingNovogen (ASX:NRT) has initiated a placement to raise up to $7.5m to take Cantrixil into phase I trials in ovarian cancer and abdominal cavity cancers.
Clinical Genomics signs China partner for FIT
31 October, 2014 by Dylan Bushell-EmblingClinical Genomics has appointed BioChain Group as the exclusive Chinese distributor for its faecal immunochemical colorectal cancer screening test.
Patrys names Roger McPherson interim CEO
29 October, 2014 by Dylan Bushell-EmblingPatrys (ASX:PAB) has appointed an interim CEO to ensure an orderly transition once it chooses a permanent replacement for outgoing chief Dr Marie Roskrow.
VivaGel condoms on sale at Woolworths: Starpharma
29 October, 2014 by Dylan Bushell-EmblingStarpharma (ASX:SPL) is set to start reaping royalties from partner Ansell's sales of VivaGel coated condoms and has received a $4.2m R&D tax incentive rebate for FY14.
Alchemia shares sink on negative trial result
28 October, 2014 by Dylan Bushell-EmblingAlchemia (ASX:ACL) has revealed that its phase III trial of HA-Irinotecan in metastatic colorectal cancer failed to meet the primary end point of an improvement of PFS against the control group.
